APAC's IVF market grow amidst rising infertility rates

Fertility tourism could offer lucrative opportunities for the market players.

A rise in infertility rates have helped support the growth of Asia Pacific’s in-vitro fertilization (IVF) services market, which is estimated to reach $13.5b by 2028, up from $6.24b in 2020 at a CAGR of 10.1% from 2021, according to a report from Allied Market Research.

Other factors supporting the market’s growth are a surge in gamete donations, delayed pregnancies in women, and increase in IVF success rates. However, low awareness levels and complications associated with IVF treatment hamper the market growth.

Still, fertility tourism and a growth in the number of fertility clinics are expected to open lucrative opportunities for the market players in the future.

Based on cycle type, the non-donor fresh cycle segment held the lion’s share in 2020, accounting for nearly two-thirds of the market. However, the non-donor thawed IVF cycle segment is tipped to register the highest CAGR of 10.3% during the period.

During the pandemic, several governments had imposed strict lockdown regulations, posing challenges for infertile couples to seek treatment. Patients and physicians postponed or canceled all embryo transfers.

In addition, healthcare authorities in the Asia-Pacific region recommended to suspend the initiation of new fertility treatments and follow freeze-all protocol in certain cases. However, post-lockdown, fertility clinics were reopened and were allowed to treat new patients.